Previous study in vitro showed that palbociclib in combination with hormone therapy (tamoxifen) or target therapy (trastuzumab) had an effectively inhibitory effect on ER-positive and HER2-amplified breast cancer, respectively [7]. Here, ESR1 is linked to breast cancer.